Longevity Report

Blood aging clocks have become billion-dollar tools for validating anti-aging interventions—but a growing body of evidence suggests the field may have misunderstood what these clocks measure. As the industry races ahead with clinical claims, the fundamental scientific assumptions underlying these biomarkers are being stress-tested like never before.

An aging clock wasn't used to tell time—it was used to hunt for youth. What researchers found in that search led to measurable lifespan extension in mice, peer reviewed and quantified.

For the first time, a blood protein aging clock tracks the same people across years instead of comparing different ages at one moment—revealing what actually changes in aging bodies and how much of that might respond to how we live.

Why do large dogs die younger than small dogs? New research in Science reveals the molecular basis—and exposes a key shift in aging science: from asking how to reverse the clock to understanding what sets its speed.

Blood clots and aging seemed like a problem medicine already understood. But new evidence suggests the real driver isn't where decades of research has pointed—and that shifts where treatment should aim.

A drug extended lifespan across multiple animal species, suggesting energy sensing is a fundamental lever on aging. The cross-species pattern is the strongest kind of preclinical evidence—but the mechanism and what it means are only now unfolding.

A Harvard team just found something that breaks aging research's most settled assumption. What they discovered reveals that biological age might be far more changeable than anyone thought — opening questions the field considered closed.

APOE4—the strongest genetic risk factor for Alzheimer's—just had its mechanism mapped, and what researchers found contradicts decades of disease assumptions. This isn't refinement; it's a fundamental reframing of how Alzheimer's develops.

A core aging mechanism just shifted from understood-but-untouched to directly therapeutic—and it matters because this one is actually modifiable. This week: how mechanism clarity opens pharmaceutical intervention routes, what sex differences are exposing about current biomarker frameworks, and confirmation on a GLP-1 finding that reframes how to think about that drug as an aging intervention.

What if aging isn't about damage accumulation at all, but about the loss of your cells' ability to keep time? A fundamental shift in how we understand biological aging reveals that your circadian rhythm is actually a governance structure—and when it fails, so does your body's capacity to maintain itself.